Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascepa combined with diverse lipid-lowering regimens for severe hypertriglyceridemia
ChiCTR2600134497Phase 4Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2026
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omega-3-acid triglycerides in hypertriglyceridemia and hypercholesterolemia, sponsored by Shanghai General Hospital. Primary endpoint: Percentage reduction in triglyceride levels. Started Jan 2026; status: recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
hypertriglyceridemiahypercholesterolemia
Beyond the preview
Go deeper on ChiCTR2600134497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134497.